2025-12-30 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the data you provided.

**1. Return Rate Comparison:**

*   **TMDX Overview:** TransMedics Group Inc. is a medical technology company pioneering a next-generation platform for preserving organs for transplant.
*   **TMDX Cumulative Return:** 205.68%
*   **S&P 500 (VOO) Cumulative Return:** 78.45%
*   **Divergence:** Current: 138.1, Relative Divergence: 66.1

**Analysis:** TMDX has significantly outperformed the S&P 500. The large positive divergence (138.1) indicates substantial outperformance. A relative divergence of 66.1 suggests that the current divergence is moderately high compared to its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2019-2021  | -18.0% | 83.5% | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%  | 83.5% | 95.0%  | 0.0  | 2.1    |
| 2021-2023  | 65.0%  | 80.5% | 64.0%  | 0.1  | 2.7    |
| 2022-2024  | 130.0% | 85.5% | 109.0% | 0.1  | 2.1    |
| 2023-2025  | 126.0% | 85.5% | 59.0%  | 0.3  | 4.2    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows periods of negative growth followed by strong positive growth, indicating volatility.
*   **MDD:** The Maximum Drawdown (MDD) figures are consistently high, indicating the stock experiences significant declines.
*   **Alpha:** The Alpha is positive in most periods, suggesting TMDX has generated returns above what would be expected based on market movements. However, there is a negative figure in 2019-2021.
*   **Beta:** The Beta is relatively low, suggesting the stock is less sensitive to overall market movements than the S&P 500 (VOO).
*   **Cap(B):** The market capitalization of TMDX shows consistent growth, but the latest figure shows sharp growth compared to previous years.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 124.20
*   **Last Market Data:** Price: 123.06, Previous Close: 124.20, Change: -0.92
*   **5-day SMA:** 127.28
*   **20-day SMA:** 131.54
*   **60-day SMA:** 125.80

**Analysis:** The stock price is currently below its 5-day, 20-day, and 60-day moving averages. The 5-day SMA is below the 20-day SMA, which indicates a downward trend in the short term. The 60-day SMA is closing the gap with the 20-day SMA, which confirms the downward trend. The difference between 'price' and 'previousClose' indicates that the stock is experiencing a slight short-term downward price fluctuation.

**3. RSI, PPO, and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 31.25 (Approaching Oversold)
*   **PPO:** -0.66 (Below Zero, indicating a possible downward trend)
*   **Hybrid Signal:** Buy 100% of cash (7 shares - Very Safe)
*   **Recent Relative Divergence Change:** 0.6 (+): 단기상승 (Short-term Increase)
*   **Expected Return:** 47.6%

**Analysis:** The RSI of 31.25 suggests that the stock is approaching oversold territory, potentially indicating a buying opportunity. The PPO is negative, suggesting a possible downward trend. The Market Risk Indicator (MRI) suggests that the price is relatively safe. The Hybrid Signal indicates a strong buy recommendation, allocating all available cash to the stock. The 20-day relative divergence change suggests a short-term upward movement. The high Expected Return of 47.6% suggests a potentially lucrative long-term investment.

**4. Recent News & Significant Events:**

*   **Positive Rating Upgrades:** Wall Street Zen upgraded TMDX's stock rating.
*   **Strong Growth Stock Recognition:** Yahoo Finance identified TMDX as a strong growth stock.
*   **Executive Compensation:** New hires received stock options, aligning their interests with the company's long-term performance.
*   **High Upside Potential:** Seeking Alpha estimates nearly 150% upside potential by the end of 2028.
*   **Positive Investment Returns:** Sahm reported a high return on a $1000 investment in TMDX made 5 years ago.
*   **Insider Sales:** Quiver Quantitative reported opinions on recent insider sales.

**Analysis:** The news is overwhelmingly positive, highlighting analyst upgrades, growth stock recognition, and high upside potential. The news regarding insider sales is the only point of concern, but it is not necessarily indicative of negative performance as there may be other factors involved.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean:** 1.67 (~Buy)
*   **Opinions:** 11
*   **Target Price:** Avg: 144.73 / High: 170.00 / Low: 114.00

**Analysis:** The analyst consensus is a "Buy" with a mean rating indicating a strong positive outlook. The target prices suggest significant upside potential from the current price.

**5. Comprehensive Analysis:**

TransMedics Group Inc. (TMDX) presents a mixed but overall positive picture.

*   **Strong Performance:** TMDX has significantly outperformed the S&P 500, with a high cumulative return and a large divergence.
*   **Volatile Growth:** The Alpha, Beta analysis reveals the company experiences both negative and positive growth periods.
*   **Technical Indicators:** RSI suggests it is approaching oversold territory, while the PPO suggests a downward trend.
*   **Positive News Sentiment:** Recent news coverage is overwhelmingly positive, highlighting analyst upgrades, growth potential, and positive investment returns.
*   **Analyst Confidence:** Analyst consensus is strong with a "Buy" rating and significant upside potential based on target prices.

**Overall Recommendation:**
Considering the high expected return, strong analyst consensus, positive news sentiment, and RSI, TMDX appears to be a good investment. However, investors should be aware of the stock's historical volatility and the potential risks associated with insider sales.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.